SCISPARC LTD (SPRC)
IL0010951403 - Common Stock
SciSparc to Acquire AutoMax
SciSparc to Acquire AutoMax
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE...
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical...
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients TEL AVIV,...
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE...
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment...
SciSparc files to sell 5.4M share for its holders (NASDAQ:SPRC)
SciSparc (SPRC) files prospectus for proposed resale of 5.4 million common shares by selling stockholders.
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (
SciSparc shares up on patents filed for psychedelic compounds with Clearmind (NASDAQ:SPRC)
SciSparc shares surge 45% as Clearmind Medicine files three patent applications for psychedelic drug combinations.
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (